C6 Antibody (Polyclonal)

A goat antiserum raised against human C6 protein.


Product Specifications

Citations3
Clonality

Polyclonal

Immnogen

Highly purified human C6 protein

Applications

See citations and technical data sheet for application info.

Concentration> 40 mg/mL
ConjugateUnconjugated
Cross Reactivity

Human, Baboon, Dog, Cat, Rabbit, Rat, Horse

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog NumberA307
Catalog Number (CE)N/A
Size2.0 mL
Price (USD)$230.00
Price (EURO)200,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A goat antiserum raised against human C6 protein.

Size

2.0 mL

Concentration> 40 mg/mL
ApplicationsSee citations and technical data sheet for application info.
FormLiquid. Whole Antiserum. ≤ 0.1% Sodium Azide
ClonalityPolyclonal
Immunogen

Highly purified human C6 protein

ConjugateUnconjugated
Cross ReactivityHuman, Baboon, Dog, Cat, Rabbit, Rat, Horse
Isotype

Goat IgG

Purity

N/A

SourceGoat
Specificity

The anti-human C6 polyclonal antisera was tested against normal human plasma by double immunodiffusion, one-dimensional immunoelectrophoresis, quantitative radial immunodiffusion, and quantitative rocket immunoelectrophoresis. The antiserum was determined to be monospecific for C6 at varying concentrations.

Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

C6 is a plasma glycoprotein which is present in normal human serum/plasma at approximately 60 µg/mL. Primarily synthesized in the liver, C6 is a single-chain protein with a molecular weight of approximately 105 kD. With activation of the classical or alternative pathways of the complement system, C5 convertase cleaves the C5 chain into C5a and C5b. C5b remains bound to the convertase and will combine with C6 to form a C5b,6 complex. This complex normally interacts with C7 to form C5b,6,7 that becomes partially embedded in the target cell outer membrane. If C7 is limited, the C5b,6 will dissociate from the C5 convertase. This complex is relatively stable in free-solution and can be purified. This fluid-phase C5b,6 complex can combine with C7 in the presence of biological or artificial membranes to form a membrane-bound C5b,6,7 complex, which can subsequently bind C8 and multiple C9 molecules completing the terminal pathway. The C5b,6,7,8,9, or C5b-9 complex, is also known as the Membrane Attack Complex (MAC), which causes irreversible damage to the target cell membrane.

Citations

TitleYearApplicationsSample SpeciesSampleSample Details

Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid.

2015ELISA, WBHuman

Serum

Acetyl salicylic acid dimer 5,5'-methylenebis(2-acetoxybenzoic acid) (DAS)

Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.

2014WBHuman

Red Blood Cells

PNH

CspA from Borrelia burgdorferi inhibits the terminal complement pathway.

2013IFBacteria

Borrelia burgdorferi

N/A